Dorsal Motor Nucleus Of Vagus In Parkinson Disease is a cell type relevant to neurodegenerative disease research. This page covers its role in brain function, involvement in disease processes, and significance for therapeutic strategies.
| Property | Value | [1]
|----------|-------| [2]
| Category | Autonomic Nervous System | [3]
| Location | Medulla oblongata, dorsal vagal complex | [4]
| Cell Type | Preganglionic parasympathetic neurons | [5]
| Neurotransmitter | Acetylcholine | [6]
| Function | Parasympathetic regulation of viscera | [7]
| Cranial Nerve | CN X (Vagus nerve) | [8]
| Taxonomy | ID | Name / Label |
|---|---|---|
| Cell Ontology (CL) | CL:0000100 | motor neuron |
| Database | ID | Name | Confidence |
|---|---|---|---|
| Cell Ontology | CL:0000100 | motor neuron | Medium |
| Target | Pathway | Function |
|---|---|---|
| Heart | Cardiac branches | Heart rate regulation (parasympathetic) |
| Lungs | Pulmonary branches | Bronchoconstriction |
| Stomach | Anterior/posterior vagal trunks | Gastric motility, acid secretion |
| Intestine | Enteric nerves | Peristalsis, secretions |
| Pancreas | Pancreatic branches | Insulin, glucagon regulation |
| Liver | Hepatic branches | Metabolic regulation |
The DMV is one of the first sites of alpha-synuclein pathology in PD, consistent with Braak staging:
The DMV serves as a critical hub in the proposed gut-origin hypothesis of PD:
Gut (Enteric Nervous System) → Vagus nerve → DMV →
Dorsal raphe → Locus coeruleus → Substantia nigra → Cortex
This pathway explains:
| Symptom | Prevalence | Correlation with DMV |
|---|---|---|
| Constipation | 50-80% | Early sign, pathology |
| Orthostatic hypotension | 30-50% | Autonomic failure |
| Urinary dysfunction | 40-70% | Later involvement |
| Gastroparesis | 30-50% | Vagal dysfunction |
| Excessive salivation | 30-70% | Autonomic |
| Approach | Target | Status |
|---|---|---|
| Deep brain stimulation | Not typically DMV | Motor symptoms |
| Vagus nerve stimulation | DMV | Experimental |
| L-DOPA | Nigrostriatal | Main therapy |
| Alpha-synuclein immunotherapy | Pathology | In trials |
| Model | Features |
|---|---|
| α-syn overexpression mice | GI pathology |
| MPTP model | Autonomic dysfunction |
| 6-OHDA model | Vagal lesions |
| Transgenic α-syn rats | Lewy body-like pathology |
The study of Dorsal Motor Nucleus Of Vagus In Parkinson Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Braak H, Rub U, Gai WP, Del Tredici K. Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. 2003. ↩︎
Wakabayashi K, Takahashi H, Takeda S, Ohama E, Ikuta F. Parkinson's disease: the presence of Lewy bodies in Auerbach's and Meissner's plexuses. 1988. ↩︎
Phillips RJ, Walter GC, Ringer BE, Higgs KM, Powley TL. Alpha-synuclein immunopositive aggregates in the vagus nerve in brainstem regions. 2009. ↩︎
Cersosimo MG, Benarroch EE. Neural control of the gastrointestinal tract: implications for Parkinson disease. 2018. ↩︎
Fasano A, Visanji NP, Liu LW, Lang AE, Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease. 2015. ↩︎
Travagli RA, Browning KN. What is causing the constipation in Parkinson's disease? Gastroenterology. 2017. ↩︎
Gonza JM, Savica R, Bower JH, et al. Risk of Parkinson disease in patients with constipation. 2015. ↩︎
Shannon KM, Keshavarzian A, Dodiya HB, Jakate S, Kordower JH. Is alpha-synuclein in the colon a biomarker for premotor Parkinson's disease? Evidence from 3 cases. 2012. ↩︎